By Chris Wack
Edgewise Therapeutics shares were up 10% at $7.56 after the company said it saw positive 12-month topline results from its ongoing study assessing the safety, tolerability, impact on muscle damage biomarkers, and pharmacokinetics of EDG-5506 in adults with Becker Muscular Dystrophy.
The company said its EDG-5506 is an orally administered small molecule designed to prevent contraction-induced muscle damage in dystrophinopathies including BMD and Duchenne muscular dystrophy.
The study is evaluating varying doses of EDG-5506 administered daily over 24 months in 12 adults with BMD. EDG-5506 was well-tolerated in all participants with no discontinuations or dose reductions due to adverse events.
A pivotal cohort has been added to the study and is anticipated to begin enrollment in the third quarter of 2023.
Write to Chris Wack at [email protected]
Read the full article here
